Artivion shares tumble on revenue miss and weak guidance

Published 24/02/2025, 22:18
Artivion shares tumble on revenue miss and weak guidance

ATLANTA - Artivion, Inc. (NYSE:AORT) saw its shares plunge 10% after-hours Monday after the cardiac and vascular surgery company reported fourth quarter revenue that fell short of analyst expectations and provided disappointing guidance for 2025.

The company posted Q4 revenue of $97.3 million, up 4% year-over-year but below the consensus estimate of $100.82 million. Adjusted earnings per share came in at breakeven, beating expectations for a loss of $0.06 per share.

For the full year 2025, Artivion forecasts revenue between $420 million and $435 million, with the midpoint of $427.5 million falling below Wall Street’s projection of $430.2 million.

The revenue miss and weak outlook overshadowed Artivion’s improved profitability, as adjusted EBITDA rose 15% YoY to $17.6 million in Q4.

"2024 was an excellent year for Artivion, marked by robust revenue and adjusted EBITDA growth," said Pat Mackin, Chairman, President, and CEO. However, he noted that Q4 revenues were "negatively impacted" by a late November cybersecurity incident.

On a positive note, the company highlighted regulatory progress for its AMDS Hybrid Prosthesis, receiving a Humanitarian Device Exemption from the FDA and submitting the second module of its pre-market approval application.

Despite the setback, management remains confident in achieving double-digit revenue growth and accelerated adjusted EBITDA expansion in 2025. The company expects currency headwinds to reduce reported revenue growth by approximately 2% for the year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.